Systemic Organ Communication in STEMI (SYSTEMI)

January 20, 2026 updated by: Heinrich-Heine University, Duesseldorf

Despite progress in pre-hospital care, ambulance logistics, pharmacotherapy and PPCI techniques, ST-segment elevation myocardial infarction (STEMI) continues to confer a substantial burden of morbidity and mortality.

Within the STEMI population, there is a spectrum of higher and lower risk patients. The aim of this cohort study is to collect prospectively and systematically clinical research data from STEMI patients. This cohort study is an open-end observational study to identify master switches in myocardial ischemia.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Germany
      • Düsseldorf, Germany, 40225
        • Recruiting
        • Division of Cardiology, Pulmonary Disease and Vascular Medicine
        • Contact:
          • Christian Jung, MD, PhD
        • Contact:
        • Principal Investigator:
          • Christian Jung, MD, PhD
        • Principal Investigator:
          • Malte Kelm, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients suffering from STEMI

Description

Inclusion Criteria:

  • Patients suffering from STEMI

Exclusion Criteria:

  • < 18 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Left-ventricular function
Time Frame: 6 months
  • LV-EF < 40% at 6 months
  • Δ LV-EF ≥ 5% between day 5 of hospitalization and 6 months
6 months
Left-ventricular remodeling
Time Frame: 6 months
Δ LVEDV ≥ 20% or Δ LVESV ≥ 15% between day 5 of hospitalization and 6 months
6 months
Myocardial texture
Time Frame: on day 5 of hospitalization and 6 months
  • Infarct/Scar size > 17.9% or MVO (yes) or IMH (yes) on day 5 of hospitalization or at 6 months
  • remote zone ΔECV between day 5 of hospitalization and 6 months
on day 5 of hospitalization and 6 months
Patency rate
Time Frame: 6 months
Coronary patency rate
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All cause mortaltiy
Time Frame: 12 months
All cause mortaltiy
12 months
MACCE
Time Frame: 12 months
cardiovascular death, non-fatal stroke or myocardial infarction
12 months
Re-Hospitalisation due to heart failure
Time Frame: 12 months
Re-Hospitalisation due to heart failure
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Heinrich-Heine University, Duesseldorf

Investigators

  • Principal Investigator: Christian Jung, MD, PhD, Division of Cardiology, Pulmonary Disease and Vascular Medicine
  • Study Chair: Malte Kelm, MD, Division of Cardiology, Pulmonary Disease and Vascular Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 18, 2017

Primary Completion (Estimated)

June 1, 2030

Study Completion (Estimated)

June 1, 2030

Study Registration Dates

First Submitted

May 3, 2018

First Submitted That Met QC Criteria

May 25, 2018

First Posted (Actual)

May 29, 2018

Study Record Updates

Last Update Posted (Actual)

January 22, 2026

Last Update Submitted That Met QC Criteria

January 20, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 17-018

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe